

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Childers et al.  
Application No.: To Be Assigned                      Group Art No.:  
Continuation of SN 09/706,683  
Filed:    Examiner:  
For:                      Branched Adamantyl And Noradamantyl Aryl- and  
Aralkylpiperazines With Serotonin 5-HT<sub>1A</sub> Activity  
Confirmation No.: To Be Assigned  
Customer Number: 25291

Mail Stop Patent Application  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement accompanies the new patent application submitted herewith of the following Inventors: Wayne E. Childers, Jr.; Horace Fletcher, III; Magid A. Abou-Gharbia; and John P. Yardley.

For:      Branched Adamantyl And Noradamantyl Aryl- and Aralkylpiperazines With  
Serotonin 5-HT<sub>1A</sub> Activity

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.


**CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU947816414US addressed to the Box Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

February 20, 2004  
Date

Paula L. Dickey  
Paula L. Dickey

2. ☒ Previously Cited Information  
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Serial Number 09/706,683 filed on November 6, 2000 of Wayne E. Childers, Jr.; Horace Fletcher, III; Magid A. Abou-Gharbia; and, John P. Yardley for Branched Adamantyl And Noradamantyl Aryl- and Aralkylpiperazines With Serotonin 5-HT<sub>1A</sub> Activity.
3. ☐ Newly Cited Information  
A legible copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed.
4. ☐ Concise Explanation  
Documents cited above which are not in the English Language  
a. ☐ have been explained in the specification.  
b. ☐ have an abstract (or other concise explanation) in English enclosed or, if readily available, a translation into English of the document is enclosed.
5. Form PTO-1449 is enclosed in duplicate.

  
\_\_\_\_\_  
Kimberly R. Mild  
Attorney for Applicant  
Reg. No. 39,224

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940-0874  
Tel. No. (484) 865-8610

Substitute for form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number	To Be Assigned	
				Filing Date		
				First Named Inventor	Wayne E. Childers et al.	
				Group Art Unit		
Examiner Name						
Attorney Docket Number	AM100151C1					
Sheet	1	of	1			

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	5,380,725		Abou-Gharbia et al.	01-1995	
	2.	5,420,278		Cliffe	05-1995	
	3.	5,254,552		Abou-Gharbia et al.	10-1993	
	4.	5,482,940		Abou-Gharbia et al.	01-1996	
	5.	5,486,518		Yardley et al.	01-1996	
	6.	5,519,025		Yardley et al.	05-1996	
	7.	4,873,331		Childers, Jr. et al.	10-1989	
	8.	5,340,812		Cliffe	08-1994	
	9.	4,882,432		Abou-Gharbia et al.	11-1989	
	10.	4,988,814		Abou-Gharbia et al.	01-1991	
	11.	4,001,223		Sugimoto et al.	01-1977	
	12.	4,202,898		Depoortere	05-1980	
	13.	4,797,489		Abou-Gharbia et al.	01-1989	
	14.	3,717,634		Wu et al.	02-1973	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	15.	EP	512 755	B1		12-1994		<input type="checkbox"/>
	16.	EP	395 313			10-1990		
	17.	EP	900 792			03-1999		
	18.	GB	2218988			05-1989		

### OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	19.	Mucke, Hermann A.M. "Repinotan", Current Opinion in CPNS Investigational Drugs, 1(5), 621-628 (1999)	<input type="checkbox"/>
	20.	Rasmussen, K., Annual Reports in Med. Chemistry, 30, Academic Press, NY, 1-9 (1995)	
	21.	Schaus, J.M., Annual Reports in Med. Chemistry, 33, Academic Press, NY, 21-30 (1998)	
	22.	Holt, W.F., et al., Neuroprotection in CNS Diseases, Marcel Dekker, NY 87-119 (1997)	
	23.	Engelsen, B., et al., Neurotoxicity of Excitatory Amino-Acids, Raven Press, NY 311-322 (1990)	
	24.	Ince et al., Rev. Contemp. Pharmacother., 8, 195-212 (1997)	
	25.	Meldrum, B., Prog. Brain Research., 116, 441-458 (1998)	
	26.	Koroshetz & Moskowitz, Trends in Pharmacol. Sci., 17, 227-233 (1996)	
	27.	Dunn, C.D.R., Scrip Reports, PJB Publications, Richmond (1995) Chapter Two, 61-90, Chapter Four, 149-159.	
	28.	Arowsmith, J.E. et al., Stroke, 29, 2357-2362 (1998)	
	29.	DeVry, Psychopharmacology, 121, 1-26 (1995)	
	30.	Matsuyama, S., Brain Research, 728, 175-180 (1996)	
	31.	DeVry, Drugs of the Future, 22, 341-349 (1997)	
	32.	Schechter et al., Serotonin, 2(7), 299-309 (1997)	
	33.	Lazareno et al., Br. J. Pharmacol., 109, 1120-27 (1993)	
	34.	Coyle, Harvard Rev. Psychiatry, 3(5), 241-253 (1996)	
	35.	Lucki et al., J. Pharma. & Experimental Ther., 228(1), 133-139 (1983)	
	36.	Smith, L.M. et al., Pharmacol. Biochem Behavior, 24, 1513-19 (1986)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.